NAVEGA THERAPEUTICS APPOINTS NEW STRATEGIC ADVISORS TO THE BOARD OF ADVISORS [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
4 min read Epigenetic Gene Therapy Company Adds Experienced Advisors to the Board SAN DIEGO Feb. 13, 2025 /PRNewswire/ -- Navega Therapeutics, a leading epigenetic gene therapy company, is pleased to announce the addition of four senior advisors. The addition of these experienced entrepreneurs and scientific experts will support the team on technical and business topics as the company continues to grow. Navega Therapeutics (PRNewsfoto/Navega Therapeutics) The new advisors will contribute their talents in gene therapy product development, AAV manufacturing, and business strategy with more than 125 years of combined experience in this field. Jeffrey M. Ostrove , Ph.D. currently serves on the Board of Directors of 3 biotech companies and is a co-founder of 8 additional ones. He is now the Co-Founder, President and Director of Papillon Therapeutics, a clinical stage company working on genetic treatments for inherited rare diseases. A successful serial entrepreneur Dr. Ostrove w
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.MarketBeat
- Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript [Seeking Alpha]Seeking Alpha
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- LXEO's page on the SEC website